主任药师，中山大学中山眼科中心药学部主任，生物与医药博士，硕士生导师，广东省杰出青年医学人才，广东省眼科药物创制与评价工程技术研究中心主任。一直致力于眼科创新药的研制和开发，至今已主持了30多个滴眼液的临床前研究工作，获批3个1类新药临床批件，2个2类新药临床批件，1个3类新药临床批件，14个生产批文，获得35项发明专利授权，发表14篇SCI论文，参编专著6部，承担省部级以上基金10多项，参与8项科技成果转化。研发的治疗白内障1类新药ZOC2017217滴眼液，已获得20多个国家化合物发明专利授权，获得1类新药临床批件，完成Ⅰ期和Ⅱ期临床试验并获得积极结果，已进入III期临床试验，并以13.8亿元完成转化，实现白内障治疗的重大突破。研发的治疗青光眼1类新药ZOC2019619滴眼液，获得1类新药临床批件，已进入II期临床试验，并以2.75亿元完成转化，解决我国青光眼药物的卡脖子情况。
Yandong Wang, Chief Pharmacist, Director of the Department of Pharmacy at Zhongshan Ophthalmic Center Sun Yat-sen University, Doctor of Biology and Medicine, Master Tutor, Outstanding Young Medical Talents of Guangdong Province, Director of Guangdong Ophthalmic Drug Development and Evaluation Engineering Technology Research Center. He has been applied himself to the creation and development of ophthalmic drugs.He has led more than 30 eye drops pre-clinical studies. He has obtained three first-in-class innovative drugs, two class 2 new drugs and one class 3 new drug clinical approvals and 14 drug production license. He has been granted 35 invention patents, published more than 14 SCI papers and compiled 6 monographs. He has undertaken more than 10 provincial and ministerial-level research projects and transformed 8 technology achievements. ZOC2017217 eye drops was the first-in-class innovative cataract drug，has obtained more than 20 national compound invention patents and clinical approval. It has completed Phase I and Phase II clinical trials with positive results and entered Phase III clinical trials. It has achieved a major breakthrough in cataract treatment and technology achievement transformation with 1.38 billion yuan. ZOC2019619 eye drops was the first-in-class innovative glaucoma drug，has obtained clinical approval and entered Phase II clinical trials. It has and technology achievement transformation with 275 million yuan. It has solved glaucoma drugs bottlenecks in China.
